CN103007427B - Slow controlled release in utero medicine-feeder and preparation method thereof - Google Patents
Slow controlled release in utero medicine-feeder and preparation method thereof Download PDFInfo
- Publication number
- CN103007427B CN103007427B CN201110282294.8A CN201110282294A CN103007427B CN 103007427 B CN103007427 B CN 103007427B CN 201110282294 A CN201110282294 A CN 201110282294A CN 103007427 B CN103007427 B CN 103007427B
- Authority
- CN
- China
- Prior art keywords
- controlled release
- medicine
- utero
- feeder
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention relates to slow controlled release in utero medicine-feeder, it is characterized in that, it comprises support, medicated layer and controlled release layer.The present invention also relates to the preparation method of described slow controlled release in utero medicine-feeder.Slow controlled release of the present invention in utero medicine-feeder accurately can control the release dosage of trace.
Description
(1) technical field
The present invention relates to slow controlled release in utero medicine-feeder, the invention still further relates to the preparation method of described medicament release device.
(2) background technology
Intrauterine device (IUD) applies one of wider contraceptive device, the IUD wherein discharging progestogen originates in the seventies, because such IUD plays dual parts machinery contraception and progestin contraceptive in uterus, and low dosage progestogen can alleviate the symptoms such as the hemorrhage and pain caused because of IUD, therefore have compared with Inrrt IUD and the lower pregnancy rate of Copper IUD and side effect.
Methylvinyl-polysiloxane (silicone rubber) is a class hydrophobicity non-biodegradable polymers, and biocompatibility is better, is widely used in et al. Ke shaping and controlled release drug delivery system.But as preparation release third generation progestogen as gestodene (gestodene), promise medroxyprogesterone (Normegestodene), gestrinone (R-2323), triketone desogestrel, desogestrel (De80goestral), norgestrienone (Norgestrienon), demegestone (Demegestone), promegestone (Promegestone), dydrogesterone (Isopregneone), trimegestone (Trimegestone), drospirenone (Drospirenone) etc.Answer its biological activity high, effective dose is very low, and these medicines are higher at middle silicone rubber permeability, just limit the application of these medicines.The present invention is the outer controlled release pipe that macromolecular material that permeability is lower makes in utero medicine-feeder, to reach the release dosage accurately controlling trace.
By the mode of palace intracavitary administration, the focus for the treatment of local and the disease of whole body, be widely used clinically, also some formulation products are had in the market in use, as oral contraceptive, injection-type Contraceptive, etc., but take a broad view of curative effect and the use of these formulation products, will find in its curative effect and use column defects all:
1. oral drugs are at the first pass effect of liver, and dosage is large, and drug bioavailability is low, and side reaction is large, and the curative effect of medicine cannot be made to be fully played.
2. be difficult to continue, constant effective dose administration.Every day need be administered once above.Difficulty is brought to needing the patient of long-term prescription.
The outer controlled release pipe of the in utero medicine-feeder that the macromolecular material of having tested confirmation makes has ethylene-vinyl acetate copolymer (EVA), polyethylene (PE) and polyester (PET) etc., it changes the permeability of these certain drug in release-controlled film of having illustrated, and meets the requirement of the in utero release mode that medicine-feeder is micro-, long-term, constant.And adopt hot irradiation that the controlled release layer of contraction is adhere well to change outside described medicated layer in the past in production process because these macromolecular materials cannot expand in a solvent, that is, together with critically cannot being attached to the tubulose medicated layer of internal layer, have impact on the form of the degree of accuracy of drug release, stability and outward appearance.
Described technical field is sought after adopting domestic existing plant equipment, with the vagina administration apparatus of the method producer of mold pressing, injection moulding, expressing technique, thus reduce costs and reach the release dosage, long-term, efficient, effective, the easy administration object that accurately control trace.
(3) summary of the invention
An object of the present invention is to provide processing technology simple, can accurately control the slow controlled release in utero medicine-feeder of the release dosage of trace for long term administration.
Another object of the present invention is to provide the preparation method of described slow controlled release in utero medicine-feeder.
The object of the invention is by following design realize:
A kind of slow controlled release in utero medicine-feeder, it comprises support, medicated layer and controlled release layer, described medicated layer and controlled release layer are coated on described support successively, the cross sectional shape of described support is T-shape or " r " type, described medicated layer is that the medicine of 20: 70-80: 30 and the mixture of medical grade silicon rubber are formed by ratio of weight and number, described medical grade silicon rubber is selected from HTV (high temperature vulcanized or heat cure, molecular weight 30 ~ 1,000,000), RTV-2 (double component room temperature vulcanization, molecular weight 0.74 ~ 110,000), RTV-1 is (single-component room temperature vulcanized, molecular weight 0.74 ~ 110,000) or LTV (baking, molecular weight 400 ~ 20000), Dow corning SiLastic-382 medical grade silicone rubber, Q7 medical grade silicone rubber series, implant level MDX series, the methyl vinyl silicone of medical grade, described controlled release layer is made up of macromolecule memory material, and described macromolecule memory material is selected from the ethylene-vinyl acetate copolymer of cross-linked form, polyethylene or polyester.
In one embodiment, described medicated layer is tubulose, and its internal diameter is 1-3 millimeter, and thickness is 0.2-2 millimeter, and external diameter is 2-4 millimeter.
In another embodiment, described controlled release tube layer is tubulose, and its internal diameter is 1-3.5 millimeter, and thickness is 0.2-3 millimeter, and external diameter is 2-5 millimeter.
The material of described support can be selected from the medical material of the composite of polypropylene, polyethylene, polyurethane, polypropylene and composite polyethylene material or rubber and plastics.
When described bracket cross section shape is T-shape, it comprises an a trailing arm 1a and transverse arm 1b diameter is 1.2-1.7mm, length for the trailing arm 1a described in 25-45mm be cylindrical, diameter is 1.2-2mm, is highly 25-50mm.
When described support is " r " type, it comprises a trailing arm 1a and two forearm 1b and 1b ', and described trailing arm 1a is cylindrical, diameter is 1.2-1.7mm, is highly 25-50mm, and described forearm 1b and 1b ' is circular arc, diameter is 2-4mm, and length is 25-50mm.
In general, the ethylene-vinyl acetate copolymer (the content 20-45% of vinyl acetate VA) of cross-linked form, polyethylene (low-density) or polyester (fibre strength is 5-6 gram/dawn) are buied by commercially available; Also by making linear ethylene-acetate ethylene copolymer, polyethylene or polyester change over network structure after the radiation effects of the radioactive sources such as electron accelerator, the ethylene-vinyl acetate copolymer of the cross-linked form described in formation, polyethylene or polyester.
In one embodiment, the ethylene-vinyl acetate copolymer of described cross-linked form, polyethylene or polyester shrink under the heat radiation of 80-105 DEG C, and its radial shrinkage ratio is 50%-80%.
The medicine used in the present invention can be selected from gestodene, promise medroxyprogesterone, gestrinone, triketone desogestrel, desogestrel, norgestrienone, demegestone, promegestone, dydrogesterone, trimegestone or drospirenone.
The present invention relates on the other hand the preparation method of slow controlled release in utero medicine-feeder, comprising:
A the medical material being selected from the composite of polypropylene, polyethylene, rustless steel, silicone rubber, polyurethane, polypropylene and composite polyethylene material or rubber and plastics is carried out mold pressing or injection moulding by (), obtain T-shape or " r " type support;
(b) by the methylvinyl-polysiloxane of medicine and medical grade with 20: 70-80: 30 part by weight Homogeneous phase mixing obtain mixture, then put into mould and carry out hot pressing, sulfuration, form tubulose medicated layer;
C tubulose medicated layer that step (b) obtains by () is inserted in the trailing arm middle-end of the support that step (a) obtains; Or
The mixture that step (b) obtains by (c ') injects the trailing arm middle-end of support by injection molded;
D () intercepts the cylindrical controlled release pipe comprising macromolecule memory material of external diameter 2-7mm, internal diameter 1-3mm, long 10-55mm, described macromolecule memory material is selected from the ethylene-vinyl acetate copolymer of cross-linked form, polyethylene or polyester;
E cylindrical controlled release layer that step (d) obtains by () be inserted in that step (c) or (c ') obtain with outside the product of medicated layer, hot irradiation, makes described controlled release layer adhere well to outside described medicated layer.
(4) accompanying drawing explanation
Fig. 1 is the sectional view of T-shape support.
Fig. 2 a is the cross-sectional view of the medicated layer be coated on support.
Fig. 2 b is the longitudinal section of the medicated layer be coated on support.
Fig. 3 is the sectional view of " r " support.
Fig. 4 a is the cross-sectional view of controlled release layer pipe.
Fig. 4 b is the longitudinal section of controlled release layer pipe.
Fig. 5 a is the T-shape support schematic diagram of band medicated layer.
Fig. 5 b is band medicated layer " r " type support schematic diagram.
Fig. 6 a is the schematic diagram of the slow controlled release in utero medicine-feeder with " r " type support.
Fig. 6 b is the schematic diagram of the slow controlled release in utero medicine-feeder with T-shape support.
Fig. 7 is the gestodene's in utero drug release profiles of medicine-feeder under two kinds of different macromolecular material controlled releases.
(5) detailed description of the invention
Below in conjunction with accompanying drawing, elaboration detailed is further done to the present invention.
The present invention be by macromolecular material lower for the permeabilitys such as such as ethylene-vinyl acetate copolymer (EVA), polyethylene (PE) or polyester (PET) after the radiation effects of the radioactive sources such as electron accelerator, its common linear structure is made to change over network structure, define the crosslinked of described macromolecular material, after crosslinked, these materials will possess unique " memory effect ", and the material of expansion, cooling and shaping again can shrink and return to the original form after being heated.Also known as polymer shape memory material.
Term used herein " memory effect ", when just referring to that the crystallizations such as radiant crosslinked polyethylene or amorphous polymeric materials are heated to more than fusing point, although crystal grain melts, but there is not flow regime, and there is the elasticity of rubber one class, if now make polyethylene dilating, then still expansion state can be kept after cooling and shaping, if this expansion polyethylene is reheated crystalline melting temperature, this polymeric material meeting " memory " is played original form when it is not expanded and is again shunk and recovers former state, therefore title polymer shape memory material ".The radial shrinkage ratio of shrink-down material can reach 50%-80%.
See Fig. 1, described bracket cross section shape is T-shape, and it comprises trailing arm 1a and transverse arm 1b, and its diameter is 1.2-1.7mm, and length is 25-45mm, and described trailing arm 1a is cylindrical, and diameter is 1.2-2mm, is highly 25-50mm.
See Fig. 2 a and 2b, described medicated layer is tubulose, which show the medicated layer be coated on support, and wherein medicated layer length H is the length of energy covered stent, preferably 10-30 millimeter, more preferably 15-25 millimeter., its internal diameter (A3-B3) is 1-3 millimeter, and thickness (C3-D3) is 0.2-2 millimeter, and external diameter (E3-F3) is 2-4 millimeter.
See Fig. 3, when described support is " r " type, it comprises trailing arm 1a and two forearm 1b and 1b ', described trailing arm 1a is cylindrical, and diameter is 1.2-1.7mm, is highly 25-50mm, described forearm 1b and 1b ' is circular arc, and diameter is 2-4mm, and length is 25-50mm.
See Fig. 4 a and 4b, described controlled release tube layer is tubulose, and its internal diameter (A2-B2) is 1-3.5 millimeter, and thickness (C2-D2) is 0.2-3 millimeter, and external diameter (E2-F2) is 2-5 millimeter.
Described controlled release pipe can be cylindrical controlled release layer.In one embodiment, adopt injection moulding or extrude ethylene-vinyl acetate copolymer, polyethylene or the polyester formation controlled release cylinder controlled release pipe making cross-linked form, its external diameter 2-7mm, internal diameter 1-3mm, long 10-55mm; The ethylene-vinyl acetate copolymer of described cross-linked form, polyethylene or polyester can commercially availablely be buied, such as, purchased from Changchun thermoplastic material limited company.Or, can from the cylindrical controlled release pipe of commercially available ethylene-vinyl acetate copolymer, polyethylene or the polyester of buying the cross-linked form with shape memory effect.
Based on embodiment, the invention will be further elaborated below
Embodiment 1
Containing the in utero medicine-feeder of gestodene
(1) take LTV (liquid state adds shaping) silicone rubber 2g, gestodene 2g, platinum catalyst and active hydrogen cross-linking agent in right amount each, put into grinding tool and be pressed into cylindric medicated layer by mould, external diameter 2.5mm, internal diameter 1.5mm, long 20mm.
(2) get polyethylene IUD plasticity " r " type support put into dehydrated alcohol soak within one hour, drain, for subsequent use.
(3) the cylindric medicated layer that step (1) obtains is enclosed within the trailing arm middle-end of the polyethylene IUD plasticity support that step (2) processed.
(4) external diameter 3.5mm is intercepted, internal diameter 3mm, the polyethylene cylinder shape controlled release pipe with shape memory effect of long 20mm is (purchased from the good plastic company in Wal, Wujiang, ProductName: controlled release pipe is extruded in ethylene-vinyl acetate copolymer pyrocondensation), outside the medicated layer of being inserted in the product that above-mentioned steps (3) obtains, with the hot-air radiation of 80 DEG C Celsius on controlled release pipe, it is made to recover shape memory, closely be attached at outside medicated layer, form the two ore control medicine-releasing system of compound depot and rate controlling membrane.
Embodiment 2 is containing the in utero medicine-feeder of norgestrienone
(1) norgestrienone and medical grade LS-4100 addition-type silicon rubber 1: 1 after Homogeneous phase mixing, are put into grinding tool and are pressed into cylindric medicated layer by mould, external diameter 3mm, internal diameter 1.5mm, long 20mm on rubber mixing machine.
(2) get polyethylene IUD plasticity " r " type support put into dehydrated alcohol soak within one hour, drain, for subsequent use.
(3) the cylindric medicated layer that step (1) obtains is enclosed within the trailing arm middle-end of the IUD plasticity support processed in step (2).
(4) external diameter 3.5mm is intercepted, internal diameter 3.2mm, polyethylene (PE) the cylindrical controlled release pipe with shape memory effect of long 25mm is (purchased from the good plastic company in Wal, Wujiang, controlled release pipe is extruded in ProductName polyethylene (PE) pyrocondensation), outside the medicated layer of being inserted in the product that above-mentioned steps (3) obtains, with the hot-air radiation of 105 DEG C Celsius on controlled release pipe, it is made to recover shape memory, closely be attached at outside medicated layer, form the two ore control medicine-releasing system of compound depot and rate controlling membrane.
Embodiment 3 is containing the in utero medicine-feeder of triketone desogestrel
(1) by triketone desogestrel 2 grams and medical grade LS-4100 addition-type silicon rubber 4 grams on rubber mixing machine after Homogeneous phase mixing, cylindrical shape is pressed into by mould, hot-press vulcanization becomes medicated layer, its pastille thickness 0.6mm, internal diameter are 1.5mm, external diameter is 2.7mm, then deburring, intercepts the cylindric medicated layer of the heavy 85mg of long 1.7cm.
(2) the garden tubbiness medicated layer that step (1) obtains is placed on the upper of IUD " r " type support trailing arm.
(3) intercept that internal diameter is 3mm, external diameter is 3.2mm, polyester (PET) the cylindrical controlled release pipe with shape memory effect of long 2cm is (purchased from the good plastic company in Wal, Wujiang, ProductName: controlled release pipe is extruded in polyester (PU) pyrocondensation, outside the medicated layer of being inserted in the product that above-mentioned steps (3) obtains, with the hot-air radiation of 100 DEG C Celsius on controlled release pipe, it is made to recover shape memory, closely be attached at outside medicated layer, form the two ore control medicine-releasing system of compound depot and rate controlling membrane.
Embodiment 4
Containing the in utero medicine-feeder of gestodene
(1) take LTV (liquid state adds shaping) silicone rubber 2g, gestodene 2g, platinum catalyst and active hydrogen cross-linking agent in right amount each, put into grinding tool and be pressed into cylindric medicated layer by mould, external diameter 2.5mm, internal diameter 1.5mm, long 20mm.
(2) get polyethylene IUD plasticity " r " type support put into dehydrated alcohol soak within one hour, drain, for subsequent use.
(3) the cylindric medicated layer that step (1) obtains is enclosed within the trailing arm middle-end of the polyethylene IUD plasticity support that step (2) processed.
(4) external diameter 3.5mm is intercepted, internal diameter 3mm, the polyethylene cylinder shape controlled release pipe with shape memory effect of long 20mm is (purchased from the good plastic company in Wal, Wujiang, ProductName: controlled release pipe is extruded in ethylene-vinyl acetate copolymer pyrocondensation, outside the medicated layer of being inserted in the product that above-mentioned steps (3) obtains, with the hot-air radiation of 80 DEG C Celsius on controlled release pipe, it is made to recover shape memory, closely be attached at outside medicated layer, form the two ore control medicine-releasing system of compound depot and rate controlling membrane.
Comparative example 1
Containing the in utero medicine-feeder of gestodene
(1) take LTV (liquid state adds shaping) silicone rubber 2g, gestodene 2g, platinum catalyst and active hydrogen cross-linking agent in right amount each, put into grinding tool and be pressed into cylindric medicated layer by mould, external diameter 2.5mm, internal diameter 1.5mm, long 20mm.
(2) get polyethylene IUD plasticity " r " type support put into dehydrated alcohol soak within one hour, drain, for subsequent use.
(3) the cylindric medicated layer that step (1) obtains is enclosed within the trailing arm middle-end of the polyethylene IUD plasticity support that step (2) processed.
(4) intercept external diameter 3.5mm, the silicone rubber controlled release pipe of internal diameter 3mm, long 20mm (this making in laboratory extrude controlled release, outside the medicated layer of being inserted in the product that above-mentioned steps (3) obtains after swelling with petroleum ether, after its volatilization.Make it recover shape memory, be closely attached at outside medicated layer, form the two ore control medicine-releasing system of compound depot and rate controlling membrane.
Dissolution test 1
To the radial extracorporeal releasing test of the in utero medicine-feeder of gestodene prepared by embodiment 4 and comparative example 1.
Instrument: 1, HPLC Shimadzu LC-10AT
2, constant temperature water bath shaker
Method:
Getting nylon filament one will by test specimen (product of embodiment 4 and comparative example 1) hanging in the white wide mouthed bottle of 125ml, placing 20ml distilled water is medium, design temperature is 37 DEG C, oscillation rate 60 beats/min, continuous oscillation, after 24 hours, takes out underproof in utero medicine-feeder.
With C-18-250mn analytical column (Shimadzu), setting HPLC testing conditions is: wavelength 240nm, sensitivity 0.01AUFS, flow velocity 1ml/ minute, sample size 25 μ l, time to peak 6.78 minutes.
Get standard substance 0.22 μ g/ml, sample introduction 25 μ l records about AREA:18152, compiles ID and shows to obtain the content of gestodene in 20ml.
Get test sample 50 μ l every day, measure its of burst size every day, draw to obtain external drug release profiles, see Fig. 7.
Result shows: with the pastille in utero medicine-feeder that the inventive method is obtained, substantially reaches tablets in vitro curve that is long-term, stable state; Two kinds of different materials burst sizes differ more than 10 times, and EVA thermoplastic controlled release pipe release behavior is more stable.
Claims (10)
1. a slow controlled release in utero medicine-feeder, it comprises support, medicated layer and controlled release layer, described medicated layer and controlled release layer are coated on described support successively, the cross sectional shape of described support is T-shape or " r " type, it is characterized in that, described medicated layer is that the medicine of 20:70 to 80:30 and the methyl vinyl silicone mixture of medical grade are formed by ratio of weight and number, described controlled release layer is made up of macromolecule memory material, and described macromolecule memory material is selected from the ethylene-vinyl acetate copolymer of cross-linked form.
2. slow controlled release according to claim 1 in utero medicine-feeder, it is characterized in that, described medicated layer is tubulose, and its internal diameter (A3-B3) is 1-3 millimeter, thickness (C3-D3) is 0.2-2 millimeter, and external diameter (E3-F3) is 2-4 millimeter.
3. slow controlled release according to claim 1 in utero medicine-feeder, is characterized in that, the material of described support is selected from the medical material of polypropylene, polyethylene and polyurethane.
4. slow controlled release according to claim 1 and 2 in utero medicine-feeder, it is characterized in that, when described bracket cross section shape is T-shape, it comprises a trailing arm (1a) and a transverse arm (1b), the diameter of described transverse arm is 1.2-1.7mm, and length is 25-45mm, and described trailing arm (1a) is for cylindrical, diameter is 1.2-2mm, is highly 25-50mm;
When described support is " r " type, it comprises a trailing arm (1a) and two forearm (1b, 1b '), described trailing arm (1a) is for cylindrical, and diameter is 1.2-1.7mm, is highly 25-50mm, described forearm (1b, 1b ') be circular arc, diameter is 2-4mm, and length is 25-50mm.
5. slow controlled release according to claim 1 and 2 in utero medicine-feeder, is characterized in that, by making linear ethylene-acetate ethylene copolymer change over network structure after radioactive source radiation, and the ethylene-vinyl acetate copolymer of the cross-linked form described in formation.
6. slow controlled release according to claim 1 in utero medicine-feeder, is characterized in that, the ethylene-vinyl acetate copolymer of described cross-linked form shrinks under the heat radiation of 80-105 DEG C, and its radial shrinkage ratio is 50%-80%.
7. slow controlled release according to claim 1 in utero medicine-feeder, it is characterized in that, described medicine is selected from gestodene, promise medroxyprogesterone, gestrinone, triketone desogestrel, desogestrel, norgestrienone, demegestone, promegestone, dydrogesterone, trimegestone or drospirenone.
8. the preparation method of the in utero medicine-feeder of the slow controlled release as described in as arbitrary in claim 1-7, comprising:
A the medical material being selected from polypropylene, polyethylene and polyurethane is carried out mold pressing or injection moulding by (), obtain T-shape or " r " type support;
B the methylvinyl-polysiloxane of medicine and medical grade is obtained mixture with the part by weight Homogeneous phase mixing of 20:70 to 80:30 by (), then put into mould and carry out hot pressing, sulfuration, forms tubulose medicated layer;
C tubulose medicated layer that step (b) obtains by () is inserted in the trailing arm middle-end of the support that step (a) obtains; Or
The mixture that step (b) obtains by (c ') injects the trailing arm middle-end of support by injection molded;
D () intercepts the cylindrical controlled release pipe comprising macromolecule memory material of external diameter 2-7mm, internal diameter 1-3mm, long 10-55mm, described macromolecule memory material is selected from the ethylene-vinyl acetate copolymer of cross-linked form;
E cylindrical controlled release layer that step (d) obtains by () be inserted in that step (c) or (c ') obtain with outside the product of medicated layer, hot irradiation, makes described controlled release layer adhere well to outside described medicated layer.
9. method according to claim 8, is characterized in that, described hot irradiation temperature is 80-105 DEG C.
10. method according to claim 9, wherein said hot irradiation hot-air carries out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110282294.8A CN103007427B (en) | 2011-09-21 | 2011-09-21 | Slow controlled release in utero medicine-feeder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110282294.8A CN103007427B (en) | 2011-09-21 | 2011-09-21 | Slow controlled release in utero medicine-feeder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103007427A CN103007427A (en) | 2013-04-03 |
| CN103007427B true CN103007427B (en) | 2016-01-20 |
Family
ID=47956881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110282294.8A Active CN103007427B (en) | 2011-09-21 | 2011-09-21 | Slow controlled release in utero medicine-feeder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103007427B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200144138A (en) * | 2018-04-19 | 2020-12-28 | 이푸룬 (상하이) 바이오테크놀러지 컴퍼니 리미티드 | Elastic film having a function of reactivating the function of the endometrial base layer in the uterine cavity, and a method for manufacturing the same |
| CN110624137B (en) * | 2019-10-28 | 2022-07-01 | 易浦润（上海）生物技术有限公司 | Uterine stent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888975A (en) * | 1972-12-27 | 1975-06-10 | Alza Corp | Erodible intrauterine device |
| CN1125403A (en) * | 1993-06-17 | 1996-06-26 | 雷若斯公司 | Intravaginal delivery system |
| CN1548014A (en) * | 2003-05-08 | 2004-11-24 | 上海市计划生育科学研究所 | Making process of intrauterine medicine releasing device |
| CN1899643B (en) * | 2005-07-20 | 2010-12-29 | 上海市计划生育科学研究所 | Pessary or intrauterine medicine release device containing antiestrogenic and anti-pregnant hormone composite preparation and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031014A1 (en) * | 2004-06-26 | 2006-01-12 | Raumedic Ag | Device for targeted liberation of substances in a cavity |
| TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
-
2011
- 2011-09-21 CN CN201110282294.8A patent/CN103007427B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888975A (en) * | 1972-12-27 | 1975-06-10 | Alza Corp | Erodible intrauterine device |
| CN1125403A (en) * | 1993-06-17 | 1996-06-26 | 雷若斯公司 | Intravaginal delivery system |
| CN1548014A (en) * | 2003-05-08 | 2004-11-24 | 上海市计划生育科学研究所 | Making process of intrauterine medicine releasing device |
| CN1899643B (en) * | 2005-07-20 | 2010-12-29 | 上海市计划生育科学研究所 | Pessary or intrauterine medicine release device containing antiestrogenic and anti-pregnant hormone composite preparation and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103007427A (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Manoukian et al. | Biodegradable polymeric injectable implants for long‐term delivery of contraceptive drugs | |
| US4888074A (en) | Therapeutic rings | |
| US4069307A (en) | Drug-delivery device comprising certain polymeric materials for controlled release of drug | |
| US3903880A (en) | Intrauterine device for managing the reproductive process | |
| US4016251A (en) | Vaginal drug dispensing device | |
| US4144317A (en) | Device consisting of copolymer having acetoxy groups for delivering drugs | |
| AU2005224056B2 (en) | Drug delivery system based on polyethylene vinylacetate copolymers | |
| US4344431A (en) | Polymeric article for dispensing drugs | |
| Lotfipour et al. | Freeze-thaw-induced cross-linked PVA/chitosan for oxytetracycline-loaded wound dressing: The experimental design and optimization | |
| US4317447A (en) | Drug delivery system | |
| RU2541812C2 (en) | Intravaginal drug delivery system and method for making same | |
| CN105288831B (en) | A kind of biodegradation type drug delivery system of hollow tubular and preparation method thereof | |
| CN1326337A (en) | Drug delivery device, especially for delivery of progestins and estrogens | |
| DK143384B (en) | LTV ORGANOSILOXAN PREPARATION-BASED MATERIALS FOR MEDICINAL PRODUCTS | |
| MX2007011817A (en) | Methods of manufacturing a medicated tampon assembly. | |
| Feng et al. | Twin-screw extrusion of sustained-release oral dosage forms and medical implants | |
| CN103007427B (en) | Slow controlled release in utero medicine-feeder and preparation method thereof | |
| Maurizii et al. | 3D-printed EVA-based patches manufactured by direct powder extrusion for personalized transdermal therapies | |
| CN102743328B (en) | Intrauterine sustained control release drug delivery system adopting biodegradation material, and preparation method thereof | |
| CN101926783B (en) | Drug slow control releaser and preparation method thereof | |
| CN101028550A (en) | Artificial vagina feeder and its production | |
| CN1899643B (en) | Pessary or intrauterine medicine release device containing antiestrogenic and anti-pregnant hormone composite preparation and its use | |
| CN1251654C (en) | Making process of intrauterine medicine releasing device | |
| Loxley | Devices and implants prepared using hot melt extrusion | |
| CN2416900Y (en) | Local applying medicine slow-released device for treating gynecopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |